Anhco Nguyen
Direttore Tecnico/Scientifico/R&S presso ATARA BIOTHERAPEUTICS, INC.
Patrimonio netto: 305 490 $ in data 30/06/2024
Profilo
Anhco Nguyen's current job is as the Executive VP, Chief Scientific & Technical Officer at Atara Biotherapeutics, Inc. Dr. Nguyen's former jobs include being the Vice President-Research & Development at Enumeral Biomedical Holdings, Inc. from 2014 to 2016, an Associate at the Center for Cancer Research at Massachusetts Institute of Technology, and a Vice President at Fate Therapeutics, Inc. Dr. Nguyen holds a doctorate degree from the University of Washington and an undergraduate degree from Harvard College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 16/05/2024 | 35 940 ( 0.73% ) | 305 490 $ | 30/06/2024 |
Posizioni attive di Anhco Nguyen
| Società | Posizione | Inizio |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 10/05/2021 |
Precedenti posizioni note di Anhco Nguyen
| Società | Posizione | Fine |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Direttore Tecnico/Scientifico/R&S | 17/08/2016 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formazione di Anhco Nguyen
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
- Borsa valori
- Insiders
- Anhco Nguyen
